What is required to advance data ethics, data sharing, and Open Science across LMICs
What is required to advance data ethics, data sharing, and Open Science across LMICs
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer
Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer
Treatment decision guided by CTC count may improve long-term outcomes for mBC
Access to Oncology Medicines Coalition - The Medicines Patent Pool
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer
ESMO 2022: Breast and ovarian trial analysis
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer